

21 **Abbreviations:** CCP: COVID-19 convalescent plasma; nAb: neutralizing antibodies; VOC: variant
22 of concern.

23 **Keywords:** convalescent plasma; COVID-19; SARS-CoV-2; immunosuppression.

24 **Author contributions:** J.W.S. and M.Z. performed literature searches; C.M. and M.C. performed
25 statistical analyses; M.F. and D.F. wrote the first draft; A.C. and M.J.J. revised the final version.

26 **Abstract**

27 Immunosuppressed patients have increased risk for morbidity and mortality from COVID-19
28 because they less frequently mount antibody responses to vaccines and often cannot tolerate small-
29 molecule antivirals. The Omicron variant of concern of SARS-CoV-2 has progressively defeated
30 anti-Spike mAbs authorized so far, paving the way to a return to COVID-19 convalescent plasma
31 (CCP) therapy. In this systematic review we performed a metanalysis of 9 controlled studies
32 (totaling 535 treated patients and 1365 controls and including 4 randomized controlled trials), an
33 individual patient data analysis of 125 case reports/series (totaling 265 patients), and a descriptive
34 analysis of 13 uncontrolled large case series without individual patient data available (totaling 358
35 patients). The metanalysis of controlled studies showed a risk ratio for mortality of 0.65 (risk
36 difference -0.11) in treatment with CCP versus standard of care for immunosuppressed COVID-19
37 patients. On the basis of this evidence, we encourage initiation of high-titer CCP from vaccinees
38 ('hybrid plasma') in immunocompromised patients.

39 **Introduction**

40 In December 2019, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in
41 Wuhan (China)^{1,2}, causing coronavirus disease 2019 (COVID-19). It rapidly spread across the globe
42 leading to a pandemic with currently nearly 577 million infected people worldwide and 6.4 million
43 deaths³. A number of treatments, including antiviral, anticoagulant and anti-inflammatory agents
44 have been tested in COVID-19 patients, with often controversial results⁴. The passive transfer of
45 anti-SARS-CoV-2 neutralizing antibodies (nAb) from plasma of recently recovered individuals
46 (COVID-19 convalescent plasma, CCP) to patients with severe COVID-19 was among the first
47 therapies used⁵⁻⁷. Nowadays we know that such antibody-based treatment, when administered early
48 (within 72 hours since onset of symptoms) and with high titers of neutralizing antibodies (nAb),
49 leads to clinical benefit^{8,9}.

50 In spite of the marketing of monoclonal antibodies (mAbs) against COVID-19 since February 2021,
51 the high mutation rate of SARS-CoV-2 (approximately a novel variant of concern (VOC) every 6
52 months) progressively escaped most, if not all, mAbs¹⁰. By contrast, thanks to the prompt
53 availability of CCP against emerging VOCs, CCP maintained its efficacy over time by following
54 the ongoing Spike protein evolution. As a result, since the beginning of 2022 there has been a
55 renewed interest toward CCP use, particularly for immunocompromised patients, who are not able
56 to mount a sufficiently protective antibody response against the virus and have contraindications or
57 side effects from small molecule antivirals^{11,12}. These patients are at higher risk for morbidity and
58 mortality from COVID-19¹³. A few controlled studies and a number of case reports and case series
59 have shown a clinical benefit from CCP use for COVID-19 patients with hematological or solid
60 cancer or other underlying causes of immunosuppression. For such reasons, on January 2022 the US
61 Food and Drug Administration (FDA) revised the Emergency Use Authorization (EUA) of CCP to
62 include those hospitalized with impaired humoral immunity¹⁴.

63 To further summarize the heterogeneous literature data on the CCP use in immunocompromised
64 patients, possibly identifying factors involved in more favorable outcomes, we have performed here
65 a systematic literature review.

66 **Materials and methods**

67 *Search criteria*

68 In this systematic review, we investigated the impact of CCP on COVID-19 mortality in patients
69 with primary (i.e., inheritable) or secondary immunosuppression (i.e., related to haematological or
70 solid cancers, autoimmune disorders or organ transplants). For this purpose, an electronic literature
71 search through the online PubMed and MEDLINE databases was initiated for articles published
72 from January 1, 2020 to August 12, 2022, using English language as the only restriction. The
73 Medical Subject Heading (MeSH) and keywords used were: (“COVID-19” OR “SARS-CoV-2” OR
74 “coronavirus disease 2019”) AND (“convalescent plasma” OR “immune plasma” OR
75 “hyperimmune plasma”) AND (“immunosuppression” OR “immunodeficiency” OR
76 “immunocompromised” OR “cancer” OR “transplant” OR “malignancy” OR “hematological” OR
77 “oncologic” OR “lymphoma” OR “leukemia” OR “myeloma” OR “agammaglobulinemia” OR
78 “hypogammaglobulinemia” OR “common variable immunodeficiency” OR “autoimmune
79 disorder”). Relevant articles and data were also identified through non-systematic searches in
80 Google Scholar and medRxiv, including abstracts of congress presentations which were not
81 published yet. We also screened the reference list of reviewed articles for additional studies not
82 captured in our initial systematic literature search. To be considered eligible for inclusion, studies
83 must include: 1) patients with primary or secondary immunosuppression with a confirmed diagnosis
84 of COVID-19; 2) CCP as a COVID-19 treatment; and 3) information on patients’ outcome. To
85 perform a comprehensive analysis, the retrieved literature was grouped into three different strata,
86 according to information characteristics: 1) controlled trials underwent a quantitative analysis

87 (meta-analysis); 2) large case series with aggregated data underwent a descriptive analysis; and 3)
88 case reports and case series with individual patient data underwent a single patient analysis.

89 Articles underwent a reciprocally blind evaluation for inclusion by two assessors (J.W.S. and M.F.)
90 and disagreements were resolved by a third senior assessor (D.F.). A PRISMA flowchart for this
91 review is available in Figure 1. The following data, when available, were searched for each case:
92 patient's sex and age, the underlying primary or secondary immunodeficiency, the 11-point WHO
93 COVID-19 disease severity score ¹⁵, the need for mechanical ventilation, survival at the end of
94 follow-up, the number of CCP units transfused, the volume of each CCP unit, the total CCP volume
95 transfused, the antibody level (either nAb titer or anti-Spike IgG levels) and the antibody test used,
96 time from admission to CCP transfusion, time from symptom onset to CCP transfusion, rapid
97 clinical improvement (defined as a reduction in supplemental oxygen requirements \leq 5 days post-
98 CCP transfusion), duration of follow-up (days), need for admission to intensive care unit (ICU),
99 ICU length of stay (days; total and after CCP transfusion), concomitant COVID-19 antiviral
100 treatments (intravenous immunoglobulins, remdesivir, hydroxychloroquine, anti-Spike mAbs), and
101 specific immunosuppressive drugs (anti-CD20 mAbs).

102

103 *Systematic review of comparative studies*

104 We have considered both RCTs and non-RCT. Two review authors (MF, MC) independently
105 assessed the risk of bias (ROB) of each included study following the domain-based evaluation
106 described in the *Cochrane Handbook for Systematic Reviews of Interventions*. [Higgins, J.P., Green,
107 S. (eds.): *Cochrane Handbook for Systematic Reviews of Interventions* – Version 5.1.0 [updated
108 March 2011]. The Cochrane Collaboration <http://www.cochranehandbook.org>.].

109 Within-trial ROB was assessed, using the Cochrane ROB tool for RCTs and the ROBINS-I tool for
110 non-RCTs.[Higgins, J.P., Green, S. (eds.): *Cochrane Handbook for Systematic Reviews of*

111 Interventions – Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
112 <http://www.cochranehandbook.org>]. The Cochrane 'Risk of bias' tool for RCTs addresses six
113 specific domains: sequence generation, allocation concealment, blinding, incomplete data, selective
114 outcome reporting, and other issues relating to bias. The methodological quality of observational
115 studies was assessed with the ROBINS-1 tool¹⁶. This tool includes seven specific bias domains,
116 pre-intervention and post-intervention. The domains are: (1) confounding; (2) selection of
117 participants; (3) classification of intervention; (4) deviation from interventions (o biases that arise
118 when there are systematic differences between the care provided to experimental intervention and
119 comparator groups, beyond the assigned interventions); (5) missing outcome; (6) measurement of
120 outcomes; (7) selection of reported result overall. For both RCTs and non-RCTs we have presented
121 our assessment of risk of bias using two 'Risk of bias' summary figures: 1) a summary of bias for
122 each item across all studies; and 2) a cross-tabulation of each trial by all the 'Risk of bias' items.

123

124 *Effect of intervention*

125 Measures of treatment effect were risk ratio (RR) and mean difference (MD). The study weight was
126 calculated using the Mantel-Haenszel method. We assessed statistical heterogeneity using t^2 ,
127 Cochran's Q and I^2 statistics¹⁷. The I^2 statistic describes the percentage of total variation across
128 trials due to heterogeneity rather than sampling error. In the case of no heterogeneity or moderate
129 heterogeneity ($I^2 < 40$), studies were pooled using a fixed-effects model. Where values of I^2 were
130 > 40 , a random-effects analysis was undertaken.

131

132 *'Summary of findings' tables*

133 For the outcome mortality, we used the principles of the GRADE system to assess the quality of
134 the body of evidence associated with specific outcomes and constructed 'Summary of findings'
135 tables using REVMAN 5.4^{18,19}. These tables present key information concerning the certainty of
136 the evidence, the magnitude of the effects of the interventions examined, and the sum of available

137 data for the main outcomes. The 'Summary of findings' tables also include an overall grading of the
138 evidence related to each of the main outcomes using the GRADE approach, which defines the
139 certainty of a body of evidence as the extent to which one can be confident that an estimate of effect
140 or association is close to the true quantity of specific interest. The certainty of a body of evidence
141 involves consideration of within-trial risk of bias (methodological quality), directness of evidence,
142 heterogeneity, precision of effect estimates, and risk of publication bias.

143

144 *Statistical analysis of individual patient data*

145 In the descriptive statistics of individual patient data, continuous variables were reported as mean
146 (\pm SD) or median (range) as appropriate according to distribution, while categorical variables were
147 reported as numbers and percentages.

148 An exploratory analysis on the main theme was done on the mortality after discretizing the total
149 volume, as \leq 200 ml to 1800 ml with serial increases of 200 ml. Then, a breakpoint at 600 ml of
150 CCP was tentatively posed, allowing to compare the mortality when the CCP was under or over the
151 level by Fisher exact test.

152 The basic model consisted in a logistic regression using mortality as dependent variable, and total
153 volume as predictor. The CCP total volume was expressed in units of 100 ml ("totvol100"), for ease
154 of interpretation. The potential additive independent effects of "Age", "Sex", "Time from admission
155 to transfusion", "Rapid improvement (within 5 days)", "ICU length of stay", "Steroids",
156 "Remdesivir", "(Hydroxy)chloroquine", "Antibiotics", "Anti-CD20", and "Category" were
157 evaluated.

158 In power analysis, the total sample size was calculated in order to detect an experimental-group
159 proportion of 0.06 as death rate, with the control-group proportion of 0.08, assuming a one-sided
160 hypothesis test with a 5% significance level, focusing a desired power of 80%, and if both groups

161 (treated and untreated) had the same number of observations. This would correspond to the
162 prevention of 25% of the basal deaths, or a risk ratio (RR) of 0.75.

163 Stata 17.0 was used for all statistical calculations.

164

165 **Results**

166 The literature search yielded 147 eligible studies, of which 9 controlled trials (4 randomized trials
167 ²⁰⁻²³ and 5 cohort studies ²⁴⁻²⁸) were selected for meta-analysis, 13 uncontrolled large case series
168 without individual patient data but totaling 358 patients were selected for descriptive analysis ²⁹⁻⁴¹,
169 and 125 case reports/series totaling 265 patients met the eligibility criteria for individual patient
170 data analysis, ^{35,42-165}. Reference ³⁵ was included in both the descriptive analysis and the individual
171 patient data analysis because individual patient data were available only for a subgroup of patients.

172 In the metanalysis of the 9 controlled trials (totaling 535 patients treated with CCP and 1365
173 controls), the main findings are summarized in Table 1. As shown in Figure 2 the level of evidences
174 was generally moderate because of a moderate ROB (Figure 2). Despite this, there is a high level of
175 concordance among study outcomes, with a risk difference of -0.11, and a risk ratio of 0.65 (Figure
176 3). We note that several cohort studies, despite being defined as propensity-score matched²⁸, did not
177 match for concomitant antivirals (potentially masking CCP efficacy) or B-cell depleting agents. In
178 sensitivity analysis, exclusion of individual studies did not affect significantly the effect size.

179 The demographic and clinical characteristics of the individual patient data are summarized in Table
180 3 and are available individually in Supplementary Table 1. The median age was 55 years (range 1-
181 88 years). The male/female ratio was 1.5 (161 males and 105 females). Mean WHO disease severity
182 score was 4.4, with approximately one quarter of patients (51/218) being in ICU on mechanical
183 ventilation. The reported mortality rate was 11.6% (31/265). Forty-seven patients (17.7%) had a
184 primary immunosuppression, mostly agammaglobulinemia (20/47, 42.6%) or common variable

185 immunodeficiency (22/47, 4.8%). The remaining 219 patients had secondary immunosuppression,
186 related to hematological malignancies (134/219, 61.2%), solid cancers (6/219, 2.7%), solid organ
187 transplants (65/219, 29.7%), autoimmune disorders (12/219, 5.5%) or other chronic infectious
188 disease (2/219, 0.9%) (see Table 1). Regarding treatments, the majority of patients (142/265,
189 53.4%) received steroids as part of the anti-COVID-19 therapy, while 41.7% of them (111/265)
190 received remdesivir and 47% antibiotics (125/265). Approximately one fifth of patients (45/265)
191 also received intravenous immunoglobulin, while a minority of them (11/265, 4.1%) were treated
192 with anti-Spike mAbs: interestingly, in 7 of such cases (7/11, 63.6%), CCP was given as rescue
193 therapy after mAb failure and all 7 patients survived. Nearly 20% of patients (47/265) were under
194 chemotherapy, which in the majority of the cases (35/47, 74.5%) included anti-CD20 mAbs (i.e.,
195 rituximab or obinutuzumab), responsible for prolonged B-cell depletion and impaired humoral
196 immune responses. Table 4 summarizes the CCP treatment-related data. The mean number of CCP
197 units transfused per patient was 2.3 (± 1.7), while the mean cumulative CCP volume transfused per
198 patient was 460 ml (± 372 ml). Unfortunately, it was not possible to calculate the mean nAb titer or
199 to correlate the patients' outcome with nAb titers due to the wide heterogeneity of tests used (virus
200 neutralization or high-throughput serology). No adverse reactions to CCP were reported. The
201 median time between symptom onset and CCP therapy was 17 days (range 1-132 days), while the
202 median time between hospital admission and CCP therapy was 11 days (0-120 days). The median
203 follow-up period of the patients included in this single patients' analysis was 19 days (range 4-263
204 days; data available for 69 patients). Fifty-six percent of the 114 evaluable patients had a rapid (≤ 5
205 days) clinical improvement following CCP transfusion. Thirty-one death events were observed (22
206 male and 9 females). On 126 cases where mortality and total volume were known, 7 death events
207 were found (6 males and 1 female). These data are reported in Table 5 and Figure 4. The 7 death
208 events were observed in the group of 92 patients where the CCP total volume did not exceed 600
209 ml. The comparison of the mortality when the CCP was under (7 events, 92 patients) or over this
210 level (zero events, 34 patients), however, was not significant. The coefficients of the basic logistic

211 model are reported in Table 6. No inferential significance was obtained. However, the coefficient of
212 “totvoll100” had a negative sign, suggesting a decrease of approximately 5% of the starting
213 probability of death for each 100 ml unit added. If the dose-response effect was real, with 600 ml of
214 CCP the mortality reduction would be 26.64%, with 1200 ml would be 46.48%, and with 1800 ml
215 would be 61.12%. Of course, this would need confirmation by a more extended number of
216 observations. Adding to the basic model the above listed covariates, “Age”, “Mechanical
217 Ventilation”, “Category=autoimmune”, “Category=solid cancer”, and “Anti-Spike mAbs” appeared
218 to predict a significant increase of mortality. By logistic model, the evaluation of the role of anti-
219 CD20 was impossible since anti-CD20 = “yes” predicted failure (survival) perfectly (nobody died if
220 treated with anti-CD20 if CCP total volume information was available). This happened with “Rapid
221 improvement”, “(Hydroxy)chloroquine”, “Category=common”, “Category=humoral” as well. In
222 contrast, failure to receive steroids or antibiotics predicted survival perfectly; in other words, deaths
223 were found only in treated people.

224 The total sample size calculated by power analysis for $RR = 0.75$ was 4,024, for $RR = 0.5$ was 870.

225

226 Discussion

227 Several scientific societies (e.g., ECIL-9¹⁶⁶, CDC/IDSA¹⁶⁷ and AABB¹⁶⁸ have recently revised
228 their guidelines to recommend usage of CCP in immunocompromised patients, especially after
229 Omicron sublineages progressively defeated mAb therapies authorized so far.

230 The hypothesis of a significant beneficial effect of CCP on mortality in immunocompromised
231 patients cannot be definitively demonstrated with the present data, but very strong elements support
232 its efficacy. The efficacy of antibody-based therapies for immunocompetent individuals is
233 predicated on early administration with sufficient dosage¹⁶⁹. This principle was validated by the
234 experience of CCP in COVID-19⁹. While several immunocompromised cases have been treated

235 with CCP derivatives (hyperimmune immunoglobulins)¹⁷⁰, CCP is superior in turnaround times
236 and inclusion of classes other than IgG¹⁷¹. However, we note that the immunosuppressed patients
237 in this study were treated relatively late after the initial symptoms (17 d) and hospital admission (11
238 d) and yet our analysis suggests a benefit for CCP. For life-threatening COVID-19 the pathogenesis
239 involves exuberant tissue-damaging inflammatory responses that follow an initial viral phase.
240 Antibody-based therapies function primarily as antiviral agents and are much less likely to be
241 affected in individuals who are in the inflammatory phase. However, immunocompromised
242 individuals are generally unable to mount strong antibody or inflammatory responses and often
243 cannot clear SARS-CoV-2. Hence, immunosuppressed patients represent a biologically different
244 population from the immunocompetent population where antibody-based therapies may retain
245 efficacy late into the course of disease.

246 The efficacy of CCP in immunosuppressed patients that had reported symptoms for weeks or
247 months paves the way to the hypothesis that CCP retains clinical efficacy until the recipient is
248 seronegative and there is no irreversible parenchymal damage. The recently reopened CCP arm of
249 the REMAP-CAP randomized controlled trial in UK will specifically target immunocompromised
250 patients in ICU focusing on CCP from vaccinated donors (so-called VaxCCP or “hybrid” plasma)
251¹⁷². While most studies reported in this systematic review used CCP from unvaccinated donors
252 (with a few exceptions^{125,152}), it is noteworthy that VaxCCP is nowadays widely available from
253 regular donors, retains higher nAb titers and efficacy against most Omicron sublineages than
254 standard CCP¹⁷³.

255

256 **COI statement:** We declare we don't have any conflict of interest related to this manuscript.

257 **Data availability statement:** This secondary research did not generate original data, which remain
258 available at the cited references.

259 **Acknowledgements:** We are grateful to Dr. Thomas Hueso who contributed to data analysis.

260

Figure 1

PRISMA flow chart for the current study.




Figure 2

Risk of bias summary for the controlled studies: review authors' judgements about each risk of bias (ROB) item according to ROBINS-I tool for each included study. Left: RCTs, analysis according to ROB assessment tool. Right: Non-RCTs. Note that although the 3 RCTs were judged at high risk of performance bias because they were open label trials, masking has unclear importance for the outcome mortality, because the risk of ascertainment bias is limited.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Bar	+	?	-	?	+	+	+
Estcourt-REMAP-CAP	+	+	-	-	+	+	+
Lacombe	+	+	-	+	+	+	+
Muller-Tidow	?	?	-	?	+	+	?

	Confounding	Selection bias	Bias in measurement classification of interventions	Bias due to deviations from intended interventions	Bias due to missing data	Bias in measurement of outcomes	Bias in selection of the reported results
Biernat	-	-	-	?	?	?	?
Cristelli	-	+	+	+	+	+	+
Hueso	-	+	+	+	+	+	+
Lanza	-	?	+	+	?	+	+
Thompson	-	-	+	?	?	-	+

Figure 3

Risk difference (top panel) and risk ratio (bottom panel) for mortality in randomized or cohort-controlled studies included in this systematic review.




Figure 4

Mortality under different levels of CCP treatment in 265 individual patients, as total volume from ≤ 200 ml to >1800 ml. Blue bars: death incidence. Orange bars: number of patients at risk at each level of CCP.




Figure 5

Predicted probability of death at various levels of CCP total volume, after logistic regression, basic model. The CCP total volume (“totvol100”) is expressed as 100 ml units. The large confidence intervals pinpoint the need for a confirmation by a more extended number of observations.




Table 1

Summary of findings for the 9 controlled studies included in the metanalysis.

Patient or population: Immunocompromised patients						
Settings: Hospitalized patients with COVID-19						
Intervention: COVID-19 convalescent plasma (CCP)						
Comparison: standard of care (SOC)						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Controls (standard of care)	Intervention (convalescent plasma)				
- All studies (RCTs and non-RCTs)	281 per 1000	183 per 1000 (from 152 to 222)	RR 0.65 (95% CIs, 0.54 to 0.79)	1900 patients (9 trials, 4 RCTs and 5 non-RCTs)	⊕⊕⊖⊖ low (downgraded twice for serious ROB)	Mortality was observed more commonly among SOC recipients compared to CP
-RCTs only	281 per 1000	183 per 1000 (from 152 to 222)	RR 0.68 (95 % CIs, 0.51/0.91)	340 participants (4 RCTs)	⊕⊕⊕⊖ moderate (downgraded for ROB)	CP reduces mortality compared to SOC
-Cohort studies only	264 per 1000	169 per 1000 (from 132 to 216)	RR 0.64 (95 % CIs, 0.50/0.82)	1560 participants (5 trials)	⊕⊕⊖⊖ low (downgraded twice for serious risk of bias)	Mortality was observed more commonly among SOC recipients compared to CCP. In sensitivity analysis, exclusion of individual studies did not affect the effect size of intervention.
- All studies	281 per	183 per 1000	RR 0.65	1900	⊕⊕⊖⊖	Mortality was

(RCTs and non-RCTs)	1000	(from 152 to 222)	(95% CIs, 0.54 to 0.79)	patients (9 trials, 4 RCTs and 5 non-RCTs)	low (downgraded twice for serious ROB)	observed more commonly among SOC recipients compared to CCP
---------------------	------	-------------------	-------------------------	--	--	---

*The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
 CI: Confidence interval; MD: Mean Difference; RR: risk ratio

GRADE Working Group grades of evidence :

- High quality: Further research is very unlikely to change our confidence in the estimate of effect
- Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- Very low quality: We are very uncertain about the estimate.

RR, risk ratio; CIs, confidence intervals; ROB, risk of bias.

Table 2

Summary of uncontrolled studies with aggregated results on the CCP use in immunocompromised patients.

First author, reference	Population	Diagnosis	COVID-19	CCP regimen	Days between symptoms and CCP	Previous/concomitant therapies	Outcome	Notes/Conclusions
Betrains ³¹	5 F, median age 37 y (range 19-67 y)	5 NHL	Severe COVID-19	4 high-titer ($\geq 1:160$ VNT) CCP units	N/A	1 steroids, 3 HCQ, 1 antibiotics, 2 remdesivir	Increase in nAb titer following CCP Overall mortality rate 1/5 (20%)	Patients with B-cell-depleted lymphomas are ideal candidates for CCP therapy
Gharbharan ²⁹	25 (15 M, 10 F), median age 53 y (IQR 44-66 y)	12 NHL 1 AL 8 AID 2 CLL 1 MS 1 AGG	19 severe COVID-19, 6 mild-moderate COVID-19	21 patients 1 CCP unit, 4 patients 2 CCP units	Median 26 d (IQR 15-34 d)	N/A	Overall mortality rate 4/25 (16%)	24/25 anti-CD20 therapy. The CCP benefit in B-cell depleted patients is present regardless of symptom duration.
Greenbaun ³⁰	44 (M 25, 19 F),	17 SC	Severe	42 patients 1	N/A	32 remdesivir, 20	Overall	Shorter time from COVID-

	median age 60 (range 37-48 y)	27 HM	COVID-19	CCP unit, 2 patients 2 CCP units		tocilizumab, 11 steroids, 1 anakinra	mortality 12/44 (27.3%)	19 diagnosis to CCP administration (≤ 3 days) was associated with better survival
Hueso ⁴¹	17 (12 M, 5 F), median age 58 y (range 35-77 y)	11 NHL 3 CLL 1 WM 1 CVID 1 MS	WHO score 4- 7	CCP units $\geq 1:40$ (VNT) or > 5.6 (ELISA)	Median 56 d (range 7-83 d)	8 steroids, 5 HCQ, 4 tocilizumab, 3 remdesivir, 2 antivirals	Rapid viral clearance following CCP Overall mortality rate 1/15 (6.7%)	15/17 previous treatment with anti-CD20 therapy. CCP is a promising therapy for COVID-19 B-cell depleted patients
Jasuja ³²	22 (N/A)	22 KTR	N/A	N/A	N/A	HCQ, steroids, antibiotics, remdesivir, tocilizumab	Overall mortality rate 7/22 (31.8%)	CCP was associated with no clinical benefit in KTR
Jeyaraman ³³	33 (23 M, 10 F), median age 62 y (range 7-80 y)	18 NHL 4 AL 7 MM 2 MPD 2 MDS	Severe COVID-19	CCP units $> 1:640$ 18 patients 1 CCP unit, 15 patients 2 CCP units	Median 4 d (range 2-25 d)	HCQ, steroids, antibiotics, remdesivir, tocilizumab	Overall 42.day mortality rate 15/33 (45.5%). No mortality difference between early (< 7 days)	Study with methodological limitations (retrospective case series)

							versus late CCP transfusion	
Levy ³⁴	50 (N/A)	23 NHL 9 MM 8 CLL 1 MPD 6 AL 2 MDS 1 HCL	40 severe/critical COVID-19; 10 mild/moderate COVID-19	N/A	N/A	Steroids, remdesivir	Overall mortality rate 16/50 (32%)	CCP was associated with no clinical benefit
Ljunquist ³⁵	28 (13 M, 15 F), median age 56 (range 16-84 y)	13 HM 5 SOT 2 PI	Severe COVID-19	76 CCP units transfused (median nAb titer 1:141). 21 patients received 3 CCP units	Median 26 d (range 6-68 d)	23 steroids, 18 remdesivir	Overall 30 days mortality rate 6/28 (21.4%)	50% (14/28) of patients received rituximab. Data not conclusive.
Magyari ³⁶	20 (13 M, 7 F), median age 56 y (range 27-76 y)	10 NHL, 1 MM 4 CLL 4 AL	18 moderate COVID-19 (WHO score 4- 5)	Median 4 CCP units (range 1-15 units)	Median 13.5 d (range 3-44 d)	17 patients received concomitant remdesivir, 20 steroids, 9 antivirals	No COVID-19 related deaths were recorded	Anti-CD20 therapy in 13/20 patients (65.0%). Clinical benefit of early combined administration of remdesivir

		1 MPD	2 severe COVID-19 (WHO score 8-9)					and CCP
Tremblay ³⁷	24 (14 M, 10 F), median age 69 y (range 31-88 y)	5 NHL 4 MM 2 AL 1 HL 1 MPD 1 CLL 10 SC	Severe COVID-19	High titer ($\geq 1:320$) CCP units	N/A	16 HCQ, 15 antibiotics, 2 remdesivir, 1 tocilizumab	Overall mortality rate 41.2% (10/24)	Clinical benefit of CCP when administered early in the COVID-19 disease course
Rodionov ³⁸	14 (7 M, 7 F), median age 65 y (IQR 58-70 y)	8 SOT 4 HSCT 2 HM	Median WHO score 5 (range 4-6)	Titer $\geq 1:40$ CCP units (VNT) 1 patient 1 CCP unit, 2 patients 2 CCP units, 11 patients 3 CCP units	N/A	N/A	Overall mortality 2/14 (14.3%). 8/14 (57.0%) showed clinical improvement on day 5 after CCP	Immunosuppressed patients are candidates for CCP treatment

Sait ³⁹	44 (N/A)	SOT	Median WHO score 4 (IQR 3-5)	N/A	N/A	Steroids, remdesivir, antibiotics	Overall mortality 3/44 (6.8%)	The use of CC is encouraged in SOT inpatients
Weinbergerova ⁴⁰	32 (19 M, 13 F), median age 57.7 y (range 25-86 y)	10 NHL 10 AL 6 MM 3 CLL 2 MPD 1 AID	16/32 (50.0%) severe COVID-19	2 units high titer ($\geq 1:160$) CCP units	N/A	Steroids, remdesivir	3/32 (9.4%)	Early COVID-19 treatment with remdesivir + high titer CCP is effective in hematological patients

Abbreviations: AL, acute leukemia; AID, autoimmune disorder; AGG, agammaglobulinemia; CCP, COVID-19 convalescent plasma; CLL, chronic lymphocytic leukemia; CVID, common variable immune deficiency; d, days; ELISA, enzyme-linked immunosorbent assay; F, females; HCL, hairy cell leukemia; HCQ, hydroxychloroquine; HL, Hodgkin’s lymphoma; HM, hematological malignancy; HSCT, hematopoietic stem cell transplantation; IQR, interquartile range; KTR, kidney transplant recipients; M, males; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPD, myeloproliferative disorders; MS, multiple sclerosis; N/A, not available; nAb, neutralizing antibody; NHL, non-Hodgkin’s lymphoma; PI, primary immunodeficiency; SC, solid cancers; SOT, solid organ transplant; VNT, viral neutralization test; WHO, World Health Organization; WM, Waldenstrom macroglobulinemia; y, years;

Table 3

Demographic and clinical characteristics of the 265 patients included in the individual patients' analysis.

Parameters	Results
Median age, years (range)	55 (1-88)
Males/females (n)	161/105
Male/female (ratio)	1.5
Mortality, n (%)	31/265 (11.6)
COVID-19 severity	
- WHO disease severity score, mean (\pm SD) ¹	4.4 (\pm 1.8)
- Mechanical ventilation, n (%)	51/218 (23.4)
- ICU length of stay, median days (range) ²	33 (6-271)
Condition, n (%)	
- Primary immunosuppression	47/265 (17.7)
Agammaglobulinemia	20/47 (42.6)
Common variable immunodeficiency	22/47 (46.8)
Others	5/47 (10.6)
- Secondary immunosuppression	219/265 (82.3)

Hematological malignancies	134/219 (61.2)
Non-Hodgkin's lymphoma	75/134 (56.0)
Chronic lymphocytic leukemia	17/134 (12.7)
Multiple myeloma	5/134 (3.7)
Myelodysplastic syndrome	2/134 (1.5)
Acute leukemia	13/134 (9.7)
Myeloproliferative disorders	3/134 (2.2)
HSCT	4/134 (3.0)
PHLH	1/134 (0.7)
Not specified	14/134 (10.4)
Solid cancers	6/219 (2.7)
Sarcoma	1/6 (16.7)
Wilm's tumor	1/6 (16.7)
Thymoma	2/6 (33.2)
Lung cancer	1/6 (16.7)
Prostate cancer	1/6 (16.7)
Solid organ transplants	65/219 (29.7)

Kidney	43/65 (66.1)
Liver	14/65 (21.5)
Heart	7/65 (10.8)
Not specified	1/65 (1.5)
Autoimmune disorders	12/219 (4.5)
Systemic lupus erythematosus	2/12 (16.7)
Sjogren syndrome	1/12 (8.3)
Rheumatoid arthritis	2/12 (16.7)
MCVD	2/12 (16.7)
Others	5/12 (41.7)
Infective	2/219 (0.9)
HIV	2/2 (100)
Concomitant therapies, n (%)	
- Remdesivir	111/265 (41.7)
- IVIG	45/265 (16.9)
- Hydroxychloroquine	40/265 (15.0)
- Steroids	142/265 (53.4)

- Anti-SARS-CoV-2 monoclonal antibodies	11/265 (4.1)
Casirivimab + imdevimab	3/11 (27.3)
Bamlanivimab	4/11 (36.4)
Bamlanivimab + etesivimab	3/11 (27.3)
Not specified	1/11 (9.0)
- Antibiotics	125/265 (47.0)
- Other therapeutics³	25/265 (9.4)
- Chemotherapy	47/265 (17.7)
Anti-CD20 monoclonal antibodies⁴	35/47 (74.5)
CAR-T	3/47 (6.4)
Others	9/47 (19.1)
- Immunosuppressive agents⁵	11/265 (4.1)

Abbreviations: SD, standard deviation; ICU, intensive care unit; HSCT, hematopoietic stem cell transplantation; MCVD, mixed collagen vascular disorder; IVIG, intravenous immunoglobulin; LMWH, low molecular weight heparin; Chimeric Antigen Receptor T-cell therapies; PHLH, primary hemophagocytic lymphohistiocytosis.

¹Data available in 40 patients.

²Data available in 27 patients.

³Including protease inhibitors, antivirals, anti-IL-1 and anti-IL-6 drugs.

⁴Rituximab or obinutuzumab.

⁵Azathioprine, tacrolimus, methotrexate, mycophenolate, infliximab.

Table 4

COVID-19 convalescent plasma treatment-related data in 265 individual patients.

Parameters	Information available for no. patients	Results
CCP transfused units, mean (\pm SD; range) ¹	153	2.3 (\pm 1.7; 1-11)
CCP total transfused volume (ml) ²	126	460 (\pm 372.0; 200-1800)
Days between symptom onset and CCP therapy, median (range) ³	188	17 (1-132)
Days between hospital admission and CCP therapy, median (range) ⁴	101	11 (0-120)
Post-CCP rapid improvement in oxygen supplementation (\leq 5 days), n (%)	114	64/114 (56.1)

Table 5

Mortality under different levels of CCP treatment, as total volume from ≤ 200 ml to >1800 ml. Seven death events (5.56%) were observed on 125 patients with available CCP total volume information.

Total Volume	Mortality	Patients
≤ 200	0	19
$>200-400$	3	43
$>400-600$	4	29
$>600-800$	0	12
$>800-1000$	0	12
$>1000-1200$	0	1
$>1200-1400$	0	0
$>1400-1600$	0	4
$>1600-1800$	0	4
>1800	0	1
Total	7	125

Table 6

Logistic regression, table of coefficients. Mortality was the dependent variable, CCP total volume was the predictor. The CCP total volume was expressed in units of 100 ml (“totvol100”). Number of obs = 125, log likelihood = -26.896492, LR chi2(1) = 0.28, P = 0.5994, Pseudo R2 = 0.0051.

Mortality	Coefficient	Std. err.	z	P	95% conf. interval	
totvol100	-0.0551	0.1156	-0.48	0.634	-0.2818	0.1716
_cons	-2.5370	0.6998	-3.63	0.000	-3.9086	-1.1654

References

1. Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. *Bmj* 2020;368:m1036. (In eng). DOI: 10.1136/bmj.m1036.
2. Peeri NC, Shrestha N, Rahman MS, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? *International journal of epidemiology* 2020;49(3):717-726. (In eng). DOI: 10.1093/ije/dyaa033.
3. World Health Organization (WHO). Coronavirus disease (COVID-19). Accessed July 10, 2022. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.
4. WHO. Therapeutics and COVID-19: living guideline. Accessed online at <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.4> on August 1, 2022.
5. Casadevall A, Pirofski L-a. The convalescent sera option for containing COVID-19. *The Journal of clinical investigation* 2020;130(4). DOI: 10.1172/JCI138003.
6. Franchini M, Focosi D, Corsini F, Cruciani M. Safety and efficacy of convalescent plasma in COVID-19: an overview of systematic reviews. *Diagnostics* 2021;11(9):1663. DOI: 10.3390/diagnostics11091663.
7. Franchini M, Liembruno GM, Piacentini G, Glingani C, Zaffanello M. The Three Pillars of COVID-19 Convalescent Plasma Therapy. *Life (Basel, Switzerland)* 2021;11(4) (In eng). DOI: 10.3390/life11040354.
8. Focosi D, Franchini M. COVID-19 convalescent plasma therapy: hit fast, hit hard! . *Vox sanguinis* 2021.
9. Focosi D, Franchini M, Pirofski LA, et al. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. *Clinical microbiology reviews* 2022:e0020021. (In eng). DOI: 10.1128/cmr.00200-21.
10. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. *The Lancet Infectious Diseases* 2022;22:S1473-3099:00311-5. DOI: 10.1016/S1473-3099(22)00311-5.
11. Focosi D, Franchini M. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. *Expert review of vaccines* 2021:1-8. (In eng). DOI: 10.1080/14760584.2021.1932475.
12. Senefeld JW, Klassen SA, Ford SK, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. *Transfusion* 2021;61(8):2503-2511. (In eng). DOI: 10.1111/trf.16525.
13. Khoury E, Nevitt S, Madsen WR, Turtle L, Davies G, Palmieri C. Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2022;5(5):e2210880. (In eng). DOI: 10.1001/jamanetworkopen.2022.10880.
14. US Food and Drug Administration (FDA). Clinical memorandum Re: EUA 26382. Product: COVID-19 Convalescent Plasma. Issued on December 27, 2021 at <https://www.fda.gov/media/141477/download>.
15. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis* 2020;20(8):e192-e197. (In eng). DOI: 10.1016/s1473-3099(20)30483-7.
16. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *Bmj* 2016;355:i4919. (In eng). DOI: 10.1136/bmj.i4919.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Bmj* 2003;327(7414):557-60. (In eng). DOI: 10.1136/bmj.327.7414.557.
18. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)*. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

19. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians? *Bmj* 2008;336(7651):995-8. (In eng). DOI: 10.1136/bmj.39490.551019.BE.
20. Bar K, Shaw P, Choi G, et al. A Randomized, Controlled Study of Convalescent Plasma for Individuals Hospitalized with COVID-19 Pneumonia. *The Journal of clinical investigation* 2021;131(24):e155114. DOI: 10.1172/JCI155114.
21. Müller-Tidow C, Janssen M, Schäkel U, et al. A randomized controlled clinical trial demonstrates that plasma from convalescent and vaccinated donors improves outcome of COVID-19 in patients with hematological disease, cancer or immunosuppression. *European Hematology Association. Vienna2022*.
22. Lacombe K, Hueso T, Porcher R, et al. Efficacy and safety of convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized clinical trial. 2022:2022.08.09.22278329. DOI: 10.1101/2022.08.09.22278329 %J medRxiv.
23. Estcourt LJ, Turgeon AF, McQuilten ZK, et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. *JAMA* 2021;326(17):1690-1702. (In eng). DOI: 10.1001/jama.2021.18178.
24. Biernat MM, Kolasińska A, Kwiatkowski J, et al. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. *Viruses* 2021;13(3) (In eng). DOI: 10.3390/v13030436.
25. Cristelli MP, Junior DML, Viana LA, et al. Efficacy of Convalescent Plasma to Treat Mild to Moderate COVID-19 in Kidney Transplant Patients: A Propensity Score Matching Analysis. *Transplantation* 2021 (In eng). DOI: 10.1097/tp.0000000000003962.
26. Thompson MA, Henderson JP, Shah PK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. *JAMA oncology* 2021 (In eng). DOI: 10.1001/jamaoncol.2021.1799.
27. Hueso T, Godron AS, Lanoy E, et al. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. *Leukemia* 2022;36(4):1025-1034. (In eng). DOI: 10.1038/s41375-022-01511-6.
28. Lanza F, Monaco F, Ciceri F, et al. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies : an Italian retrospective study. *Hematological oncology* 2022 (In eng). DOI: 10.1002/hon.3060.
29. Gharbharan A, GeurtsvanKessel CH, Jordans CCE, et al. Effects of treatment of COVID-19 with convalescent plasma in 25 B-cell depleted patients. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2021 (In eng). DOI: 10.1093/cid/ciab647.
30. Greenbaum U, Klein K, Martinez F, et al. High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients. *Frontiers in immunology* 2021:675-679. (<https://www.medrxiv.org/content/medrxiv/early/2021/03/10/2021.03.08.21252775.full.pdf>).
31. Betrains A, Godinas L, Woei AJF, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. *British journal of haematology* 2021;192(6):1100-1105. (In eng). DOI: 10.1111/bjh.17266.
32. Jasuja S, Sagar G, Bahl A, Verma S. COVID-19 Infection Clinical Profile, Management, Outcome, and Antibody Response in Kidney Transplant Recipients: A Single Centre Experience. *International journal of nephrology* 2021;2021:3129411. (In eng). DOI: 10.1155/2021/3129411.
33. Jeyaraman P, Agrawal N, Bhargava R, et al. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis* 2021:103075. (In eng). DOI: 10.1016/j.transci.2021.103075.
34. Levy I, Lavi A, Zimran E, et al. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. *Leukemia & lymphoma* 2021;62(14):3384-3393. (In eng). DOI: 10.1080/10428194.2021.1966782.

35. Ljungquist O, Lundgren M, Iliachenko E, et al. Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases. *Infectious diseases (London, England)* 2021;1-9. (In eng). DOI: 10.1080/23744235.2021.2013528.
36. Magyari F, Pinczés LI, Páyer E, et al. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies. *Annals of hematology* 2022;1-9. (In eng). DOI: 10.1007/s00277-022-04924-6.
37. Tremblay D, Seah C, Schneider T, et al. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. *Cancer medicine* 2020;9(22):8571-8578. (In eng). DOI: 10.1002/cam4.3457.
38. Rodionov RN, Biener A, Spieth P, et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. *The Lancet Microbe* 2021;2(4):e138. (In eng). DOI: 10.1016/s2666-5247(21)00030-6.
39. Sait AS, Chiang TP, Marr KA, et al. Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. *Transplantation direct* 2022;8(1):e1268. (In eng). DOI: 10.1097/txd.0000000000001268.
40. Weinbergerova B, Mayer J, Kabut T, et al. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients. *Hematological oncology* 2021;39(5):715-720. (In eng). DOI: 10.1002/hon.2908.
41. Hueso T, Poudoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. *Blood* 2020;136(20):2290-2295. (In eng). DOI: 10.1182/blood.2020008423.
42. Abid MB, Chhabra S, Buchan B, et al. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. *Hematology/oncology and stem cell therapy* 2021;14(1):65-70. (In eng). DOI: 10.1016/j.hemonc.2020.09.002.
43. Adedoyin O, Brijmohan S, Lavine R, Lisung FG. Undetectable SARS-CoV-2 active adaptive immunity-post-vaccination or post-COVID-19 severe disease-after immunosuppressants use. *BMJ case reports* 2021;14(11) (In eng). DOI: 10.1136/bcr-2021-246308.
44. Antony SJ, Singh J, de Jesus M, Lance J. Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation. *IDCases* 2020;21:e00888. (In eng). DOI: 10.1016/j.idcr.2020.e00888.
45. Avanzato VA, Matson MJ, Seifert SN, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell* 2020 (In eng). DOI: 10.1016/j.cell.2020.10.049.
46. Bakhsh A, AlSaeed M, Ibrahim MA, et al. Recovery From COVID-19 Pneumonia in a Heart Transplant Recipient: A Case Report. *Infectious diseases in clinical practice (Baltimore, Md)* 2021;29(6):e401-e403. (In eng). DOI: 10.1097/ipc.0000000000001004.
47. Balashov D, Trakhtman P, Livshits A, et al. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis* 2020;102983. (In eng). DOI: 10.1016/j.transci.2020.102983.
48. Basheer M, Saad E, Laskar O, et al. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery. *International journal of molecular sciences* 2021;22(16) (In eng). DOI: 10.3390/ijms22168902.
49. Bayrak M, Çadirici K. Successful pulsed methylprednisolone and convalescent plasma treatment in a case of a renal transplant recipient with COVID-19 positive pneumonia: a case report. *The Pan African medical journal* 2021;38:273. (In eng). DOI: 10.11604/pamj.2021.38.273.28577.
50. Bošnjak B, Odak I, Ritter C, et al. Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy. *Frontiers in immunology* 2021;12:721738. (In eng). DOI: 10.3389/fimmu.2021.721738.
51. Bronstein Y, Adler A, Katash H, Halutz O, Herishanu Y, Levytskyi K. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. *Journal of medical virology* 2022;94(3):1241-1245. (In eng). DOI: 10.1002/jmv.27445.

52. Bruiners N, Guerrini V, Ukey R, et al. Biologic correlates of beneficial convalescent plasma therapy in a COVID-19 patient reveal disease resolution mechanisms. *medRxiv* 2022 (In eng). DOI: 10.1101/2022.02.03.22269612.
53. Casarola G, D'Abbondanza M, Curcio R, et al. Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report. *Clinical infection in practice* 2021;12:100096. (In eng). DOI: 10.1016/j.clinpr.2021.100096.
54. Chen L, Zody MC, Mediavilla JR, et al. Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment. *mSphere* 2021;6(4):e0048021. DOI: 10.1128/mSphere.00480-21.
55. Choudhury A, Reddy GS, Venishetty S, et al. COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery. *Journal of clinical and translational hepatology* 2020;8(4):467-473. (In eng). DOI: 10.14218/jcth.2020.00061.
56. Christensen J, Kumar D, Moinuddin I, et al. Coronavirus Disease 2019 Viremia, Serologies, and Clinical Course in a Case Series of Transplant Recipients. *Transplantation proceedings* 2020;52(9):2637-2641. (In eng). DOI: 10.1016/j.transproceed.2020.08.042.
57. Çinar OE, Sayinalp B, Aladağ Karakulak E, et al. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis* 2020;59(5):102821. (In eng). DOI: 10.1016/j.transci.2020.102821.
58. Clark E, Guilpain P, Filip IL, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. *British journal of haematology* 2020;190(3):e154-e156. (In eng). DOI: 10.1111/bjh.16981.
59. Colombo D, Gatti A, Alabardi P, et al. COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma. *Journal of hematology* 2022;11(2):77-80. (In eng). DOI: 10.14740/jh845.
60. Cusi MG, Conticini E, Gandolfo C, et al. Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience. *BMC Infect Dis* 2021;21(1):630. (In eng). DOI: 10.1186/s12879-021-06321-2.
61. D'Abramo A, Vita S, Maffongelli G, et al. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway. *Frontiers in immunology* 2022;13:911339. (In eng). DOI: 10.3389/fimmu.2022.911339.
62. Dale M, Sogawa H, Seyedsaadat SM, et al. Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients. *Transplantation proceedings* 2021;53(4):1175-1179. (In eng). DOI: 10.1016/j.transproceed.2021.03.010.
63. Delgado-Fernández M, García-Gemar GM, Fuentes-López A, et al. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature. *Enfermedades infecciosas y microbiología clinica (English ed)* 2021 (In eng spa). DOI: 10.1016/j.eimc.2021.01.013.
64. Dell'Isola GB, Felicioni M, Ferraro L, et al. Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection. *Frontiers in pediatrics* 2021;9:712603. (In eng). DOI: 10.3389/fped.2021.712603.
65. Deveci B, Saba R. Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment: Case reports. *Medicine* 2021;100(52):e28470. (In eng). DOI: 10.1097/md.00000000000028470.
66. Di Palma M, Gentilini E, Masucci C, et al. Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report. *Mediterranean journal of hematology and infectious diseases* 2022;14(1):e2022043. (In eng). DOI: 10.4084/mjhid.2022.043.
67. Erber J, Wiessner JR, Huberle C, et al. Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19 - A case series. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis* 2021;60(6):103278. (In eng). DOI: 10.1016/j.transci.2021.103278.

68. Ferrari S, Caprioli C, Weber A, Rambaldi A, Lussana F. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. *Leukemia & lymphoma* 2021;62(6):1490-1496. (In eng). DOI: 10.1080/10428194.2021.1872070.
69. Fung M, Nambiar A, Pandey S, et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. *Transplant infectious disease : an official journal of the Transplantation Society* 2021;23(2):e13477. (In eng). DOI: 10.1111/tid.13477.
70. Furlan A, Forner G, Cipriani L, et al. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy. *Clinical lymphoma, myeloma & leukemia* 2021;21(9):e731-e735. (In eng). DOI: 10.1016/j.clml.2021.05.013.
71. Gattuso G, Schiavello E, Oltolini C, et al. Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management? *Tumori* 2021;3008916211067825. (In eng). DOI: 10.1177/03008916211067825.
72. Gordon O, Brosnan MK, Yoon S, et al. Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children. *JCI insight* 2022;7(2) (In eng). DOI: 10.1172/jci.insight.151518.
73. Gupta A, Kute VB, Patel HV, et al. Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study. *Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation* 2021;19(4):304-309. (In eng). DOI: 10.6002/ect.2020.0479.
74. Halfmann PJ, Minor NR, Haddock LA, et al. Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. 2022:2022.04.11.22272784. DOI: 10.1101/2022.04.11.22272784 %J medRxiv.
75. Hanssen JIJ, Stienstra J, Boers SA, et al. Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity? *Infectious disease reports* 2021;13(4):855-864. (In eng). DOI: 10.3390/idr13040077.
76. Hartman W, Hess A, Connor J. Use of COVID-19 Convalescent Plasma as Prophylaxis in a Patient with New Onset All. *Clin Oncol Case Rep* 2021;4.
77. Honjo K, Russell RM, Li R, et al. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. *Cell reports Medicine* 2021;2(1):100164. (In eng). DOI: 10.1016/j.xcrm.2020.100164.
78. Hovey JG, Tolbert D, Howell D, Burton's Agammaglobulinemia and COVID-19. *Cureus* 2020;12(11):e11701. (In eng). DOI: 10.7759/cureus.11701.
79. Hughes CM, Gregory GP, Pierce AB, et al. Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient. *Infection control and hospital epidemiology* 2022;43(6):820-822. (In eng). DOI: 10.1017/ice.2021.120.
80. Iaboni A, Wong N, Betschel SD. A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma. *Journal of clinical immunology* 2021;41(5):923-925. (In eng). DOI: 10.1007/s10875-021-00983-y.
81. Jamir I, Lohia P, Pande RK, Setia R, Singhal AK, Chaudhary A. Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. *Annals of hepato-biliary-pancreatic surgery* 2020;24(4):526-532. (In eng). DOI: 10.14701/ahbps.2020.24.4.526.
82. Jassem J, Marek-Trzonkowska NM, Smiatacz T, et al. Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report. *International journal of molecular sciences* 2021;22(20) (In eng). DOI: 10.3390/ijms222010934.
83. Jiang J, Miao Y, Zhao Y, et al. Convalescent plasma therapy: Helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestations and complex complications. *Clinical transplantation* 2020;34(9):e14025. (In eng). DOI: 10.1111/ctr.14025.

84. Jin H, Reed JC, Liu STH, et al. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. *The journal of allergy and clinical immunology In practice* 2020;8(10):3594-3596.e3. (In eng). DOI: 10.1016/j.jaip.2020.08.059.
85. Karaolidou F, Loutsidi NE, Mellios Z, et al. Convalescent plasma therapy in an immunocompromised patient with multiple COVID-19 flares: a case report. *Respirol Case Rep* 2021;9(12):e0858. (In eng). DOI: 10.1002/rcr2.858.
86. Karataş A, İnkaya A, Demiroğlu H, et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis* 2020;59(5):102871. (In eng). DOI: 10.1016/j.transci.2020.102871.
87. Katz-Greenberg G, Yadav A, Gupta M, et al. Outcomes of COVID-19-positive kidney transplant recipients: A single-center experience. *Clinical nephrology* 2020;94(6):318-321. (In eng). DOI: 10.5414/cn110311.
88. Keitel V, Bode JG, Feldt T, et al. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure. *Frontiers in immunology* 2021;12:645989. (In eng). DOI: 10.3389/fimmu.2021.645989.
89. Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic infection. *Nature* 2021. DOI: 10.1038/s41586-021-03291-y.
90. Kenig A, Ishay Y, Kharouf F, Rubin L. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products. *Clinical immunology (Orlando, Fla)* 2021:108723. (In eng). DOI: 10.1016/j.clim.2021.108723.
91. Ketels T, Gisolf J, Claassen M, et al. Short Communication: Prolonged COVID-19 Infection in a Patient with Newly Diagnosed HIV/AIDS. *AIDS research and human retroviruses* 2022;38(5):399-400. (In eng). DOI: 10.1089/aid.2021.0145.
92. Khan AM, Ajmal Z, Raval M, Tobin E. Concurrent Diagnosis of Acute Myeloid Leukemia and COVID-19: A Management Challenge. *Cureus* 2020;12(8):e9629. (In eng). DOI: 10.7759/cureus.9629.
93. Khatamzas E, Rehn A, Muenchhoff M, et al. Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host. 2021:2021.01.10.20248871. DOI: 10.1101/2021.01.10.20248871 %J medRxiv.
94. Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature. *Journal de mycologie medicale* 2021;31(2):101125. (In eng). DOI: 10.1016/j.mycmed.2021.101125.
95. Kluger MA, Czogalla J, Schmidt-Lauber C, et al. Convalescent plasma treatment for early post-kidney transplant acquired COVID-19. *Transplant infectious disease : an official journal of the Transplantation Society* 2021;23(4):e13685. (In eng). DOI: 10.1111/tid.13685.
96. Kremer AE, Kremer AN, Willam C, et al. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity. *European journal of immunology* 2021;51(10):2478-2484. (In eng). DOI: 10.1002/eji.202149277.
97. Lancman G, Mascarenhas J, Bar-Natan M. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. *Journal of hematology & oncology* 2020;13(1):131. (In eng). DOI: 10.1186/s13045-020-00968-1.
98. Lang-Meli J, Fuchs J, Mathé P, et al. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency. *Journal of clinical immunology* 2022;42(2):253-265. (In eng). DOI: 10.1007/s10875-021-01193-2.
99. Lazzari L, Oltolini C, Ciceri F, Giglio F. Complicated and persistent severe COVID-19 pneumonia in a recipient of allogeneic haematopoietic stem cell transplant. *BMJ case reports* 2021;14(10) (In eng). DOI: 10.1136/bcr-2021-245992.
100. Lemus HN, Alkayyali M, Kim E, Cunningham-Rundles C, Pyburn D, Abrams R. Acute Cerebellitis and Myeloradiculitis Associated With SARS-CoV-2 Infection in Common Variable Immunodeficiency-A Case Report. *The Neurohospitalist* 2022;12(2):361-365. (In eng). DOI: 10.1177/19418744211050215.

101. Lima B, Gibson GT, Vullaganti S, et al. COVID-19 in recent heart transplant recipients: Clinicopathologic features and early outcomes. *Transplant infectious disease : an official journal of the Transplantation Society* 2020;22(5):e13382. (In eng). DOI: 10.1111/tid.13382.
102. Lindemann M, Krawczyk A, Dolff S, et al. SARS-CoV-2-specific humoral and cellular immunity in renal transplant and haemodialysis patients treated with convalescent plasma. 2020:2020.12.09.20239673. DOI: 10.1101/2020.12.09.20239673 %J medRxiv.
103. London J, Boutboul D, Lacombe K, et al. Severe COVID-19 in Patients with B Cell Lymphocytosis and Response to Convalescent Plasma Therapy. *Journal of clinical immunology* 2020:1-6. (In eng). DOI: 10.1007/s10875-020-00904-5.
104. Lubnow M, Schmidt B, Fleck M, et al. Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson's disease: Balancing immunosuppression. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases* 2021;103:624-627. (In eng). DOI: 10.1016/j.ijid.2020.12.047.
105. Luetkens T, Metcalf R, Planelles V, et al. Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. *Blood advances* 2020;4(19):4864-4868. (In eng). DOI: 10.1182/bloodadvances.2020002595.
106. Madariaga MLL, Guthmiller JJ, Schrantz S, et al. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. (<https://onlinelibrary.wiley.com/doi/abs/10.1111/joim.13185>).
107. Martens T, Hens L, De Pauw M, Van Belleghem Y. Heart Transplantation Complicated by COVID-19 Infection. *The Annals of thoracic surgery* 2022;113(4):e267-e269. (In eng). DOI: 10.1016/j.athoracsur.2021.07.003.
108. Martínez-Barranco P, García-Roa M, Trelles-Martínez R, et al. Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma. *Acta haematologica* 2021 (In eng). DOI: 10.1159/000521121.
109. Martínez-Chinchilla C, Vazquez-Montero L, Palazón-Carrión N, et al. Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases. *Frontiers in immunology* 2022;13:860891. (In eng). DOI: 10.3389/fimmu.2022.860891.
110. Martinot M, Jary A, Fafi-Kremer S, et al. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2021;73(7):e1762-e1765. (In eng). DOI: 10.1093/cid/ciaa1474.
111. Mehta SA, Rana MM, Motter JD, et al. Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium. *Transplantation* 2021;105(1):216-224. (In eng). DOI: 10.1097/tp.0000000000003527.
112. Mendes-Correa MC, Vilas-Boas LSS, Bierrenbach AL, et al. Individuals who were mildly symptomatic following infection with SARS-CoV-2 B.1.1.28 have neutralizing antibodies to the P.1 variant. 2021:2021.05.11.21256908. DOI: 10.1101/2021.05.11.21256908 %J medRxiv.
113. Milošević I, Jovanović J, Stevanovic O. Atypical course of COVID-19 in patient with Bruton agammaglobulinemia. *Journal of infection in developing countries* 2020;14(11):1248-1251. (In eng). DOI: 10.3855/jidc.13840.
114. Mira E, Yarce OA, Ortega C, et al. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. *The journal of allergy and clinical immunology In practice* 2020;8(8):2793-2795. (In eng). DOI: 10.1016/j.jaip.2020.06.046.
115. Mohseni M, Albus M, Kaminski A, Harrison MF. A Case of COVID-19 Re-Infection in a Liver Transplant Patient. *Cureus* 2021;13(5):e14916. (In eng). DOI: 10.7759/cureus.14916.
116. Monrad I, Sahlertz SR, Nielsen SSF, et al. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution. *Open forum infectious diseases* 2021;8(7):ofab295. (In eng). DOI: 10.1093/ofid/ofab295.

117. Moore JL, Ganapathiraju PV, Kurtz CP, Wainscoat B. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. *The American journal of case reports* 2020;21:e927812. (In eng). DOI: 10.12659/ajcr.927812.
118. Moutinho-Pereira S, Calisto R, Sabio F, Guerreiro L. High-titre convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection. *BMJ case reports* 2021;14(8) (In eng). DOI: 10.1136/bcr-2021-244853.
119. Naeem S, Gohh R, Bayliss G, et al. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. *Transplant infectious disease : an official journal of the Transplantation Society* 2020:e13451. (In eng). DOI: 10.1111/tid.13451.
120. Nguyen MC, Lee EJ, Avery RK, et al. Transplant of SARS-CoV-2-infected Living Donor Liver: Case Report. *Transplantation direct* 2021;7(8):e721. (In eng). DOI: 10.1097/txd.0000000000001178.
121. Niu A, McDougal A, Ning B, et al. COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma. *Bone marrow transplantation* 2020:1-3. (In eng). DOI: 10.1038/s41409-020-0972-8.
122. Nussenblatt V, Roder A, Das S, et al. Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. 2021:2021.10.02.21264267. DOI: 10.1101/2021.10.02.21264267 %J medRxiv.
123. Nyström K, Hjorth M, Fust R, et al. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report. *BMC Infect Dis* 2022;22(1):362. (In eng). DOI: 10.1186/s12879-022-07323-4.
124. Oliva A, Cancelli F, Brogi A, et al. Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature. *The new microbiologica* 2022;45(1):62-72. (In eng).
125. Ordaya EE, Abu Saleh OM, Stubbs JR, Joyner MJ. Vax-Plasma in Patients With Refractory COVID-19. *Mayo Clin Proc* 2022;97(1):186-189. (In eng). DOI: 10.1016/j.mayocp.2021.11.001.
126. Ormazabal Vélez I, Induráin Bermejo J, Espinoza Pérez J, Imaz Aguayo L, Delgado Ruiz M, García-Erce JA. Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis* 2021;60(3):103104. (In eng). DOI: 10.1016/j.transci.2021.103104.
127. Pommeret F, Colomba J, Bigenwald C, et al. Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies. *Annals of Oncology* 2021. DOI: 10.1016/j.annonc.2021.07.015.
128. Prasad RM, Srivastava S, Wang E, et al. Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse. *The Permanente journal* 2021;26(1):123-131. (In eng). DOI: 10.7812/tpp/21.035.
129. Rüfenacht S, Gantenbein P, Boggian K, et al. Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series. *Infection* 2022;50(3):783-790. (In eng). DOI: 10.1007/s15010-022-01821-y.
130. Ribeiro LC, Benites BD, Ulaf RG, et al. Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma. *Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology* 2021;17(1):14. (In eng). DOI: 10.1186/s13223-021-00518-5.
131. Rnjak D, Ravlić S, Šola AM, et al. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? *Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine* 2021;28(3):264-270. (In eng). DOI: 10.1016/j.tracli.2021.04.004.
132. Rodriguez JA, Bonnanno C, Khatiwada P, Roa AA, Mayer D, Eckardt PA. COVID-19 Coinfection with Mycobacterium abscessus in a Patient with Multiple Myeloma. *Case reports in infectious diseases* 2021;2021:8840536. (In eng). DOI: 10.1155/2021/8840536.

133. Rodriguez-Pla A, Vikram HR, Khalid V, Wesselius LJ. COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review. *Rheumatology international* 2021;41(8):1509-1514. (In eng). DOI: 10.1007/s00296-021-04905-4.
134. Schenker C, Hirzel C, Walti LN, et al. Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response. *British journal of haematology* 2022;196(3):e27-e29. (In eng). DOI: 10.1111/bjh.17806.
135. Schreiber A, Elango K, Hong K, Ahsan C. Cardiac transplant recipient with COVID-19 induced acute hypoxic respiratory failure: a case report. *European heart journal Case reports* 2021;5(6):ytab217. (In eng). DOI: 10.1093/ehjcr/ytab217.
136. Sepulcri C, Dentone C, Mikulska M, et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient – a case study. *Open forum infectious diseases* 2021;ofab217:2021.01.23.21249554. DOI: 10.1101/2021.01.23.21249554 %J medRxiv.
137. Shankar R, Radhakrishnan N, Dua S, et al. Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia. *Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis* 2021;60(1):102956. (In eng). DOI: 10.1016/j.transci.2020.102956.
138. Spinicci M, Mazzoni A, Borchi B, et al. AIDS patient with severe T cell depletion achieved control but not clearance of SARS-CoV-2 infection.n/a(n/a). DOI: <https://doi.org/10.1002/eji.202149574>.
139. Steiner S, Schwarz T, Corman VM, et al. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. *Frontiers in immunology* 2022;13:840126. (In eng). DOI: 10.3389/fimmu.2022.840126.
140. Szwebel TA, Veyer D, Robillard N, et al. Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient. *Stem Cell Rev Rep* 2021;17(1):296-299. (In eng). DOI: 10.1007/s12015-020-10107-5.
141. Taha Y, Wardle H, Evans AB, et al. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. *Annals of clinical microbiology and antimicrobials* 2021;20(1):85. (In eng). DOI: 10.1186/s12941-021-00491-2.
142. Trimarchi H, Gianserra R, Lampo M, Monkowski M, Lodolo J. Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome. *Clinical kidney journal* 2020;13(5):739-741. (In eng). DOI: 10.1093/ckj/sfaa166.
143. Van Damme KFA, Tavernier S, Van Roy N, et al. Case Report: Convalescent Plasma, a Targeted Therapy for Patients with COVID and Severe COVID-19. *Frontiers in immunology* 2020;11:596761. (In eng). DOI: 10.3389/fimmu.2020.596761.
144. van Oers NSC, Hanners NW, Sue PK, et al. SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency. *Clinical immunology (Orlando, Fla)* 2021;224:108662. (In eng). DOI: 10.1016/j.clim.2020.108662.
145. Wright Z, Bersabe A, Eden R, Cap A. Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma. *Clinical lymphoma, myeloma & leukemia* 2020 (In eng). DOI: 10.1016/j.clml.2020.06.012.
146. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. *Journal of medical virology* 2020 (In eng). DOI: 10.1002/jmv.25882.
147. Zhang LB, Pang RR, Qiao QH, et al. Successful recovery of COVID-19-associated recurrent diarrhea and gastrointestinal hemorrhage using convalescent plasma. *Military Medical Research* 2020;7(1):45. (In eng). DOI: 10.1186/s40779-020-00273-5.
148. Zhang LL, Liu Y, Guo YG, et al. Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis. *Turkish journal of haematology : official journal of Turkish Society of Haematology* 2020 (In eng). DOI: 10.4274/tjh.galenos.2020.2020.0400.
149. Zimmerli A, Monti M, Fenwick C, et al. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery. *Frontiers in immunology* 2021;12:613502. (In eng). DOI: 10.3389/fimmu.2021.613502.

150. Zimmermann J, Glueck OM, Fertmann JM, et al. COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies. *Transplantation proceedings* 2022 (In eng). DOI: 10.1016/j.transproceed.2021.12.014.
151. Franchini M, Focosi D, Percivalle E, et al. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. *Viruses* 2022;14(7) (In eng). DOI: 10.3390/v14071443.
152. Belcari G, Conti A, Mazzoni A, Lanza M, Mazzetti P, Focosi D. Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia. *Life (Basel, Switzerland)* 2022;12(7) (In eng). DOI: 10.3390/life12071098.
153. Baang JH, Smith C, Mirabelli C, et al. Prolonged SARS-CoV-2 replication in an immunocompromised patient. *J Infect Dis* 2020 (In eng). DOI: 10.1093/infdis/jiaa666.
154. McKemey E, Shields AM, Faustini SE, et al. Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia. *Journal of clinical immunology* 2021;41(5):926-929. (In eng). DOI: 10.1007/s10875-021-00996-7.
155. Pal P, Ibrahim M, Niu A, et al. Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients. *Transfusion medicine (Oxford, England)* 2021;31(3):217-220. (In eng). DOI: 10.1111/tme.12729.
156. Meyts I, Bucciol G, Quinti I, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. *The Journal of allergy and clinical immunology* 2021;147(2):520-531. (In eng). DOI: 10.1016/j.jaci.2020.09.010.
157. Buckland MS, Galloway JB, Fhogartaigh CN, et al. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. *Nat Commun* 2020;11(1):6385. (In eng). DOI: 10.1038/s41467-020-19761-2.
158. Hatzl S, Eisner F, Schilcher G, et al. Response to "COVID-19 in persons with haematological cancers". *Leukemia* 2020;34(8):2265-2270. (In eng). DOI: 10.1038/s41375-020-0914-x.
159. Reuken PA, Stallmach A, Pletz MW, et al. Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection. *Leukemia* 2021;35(3):920-923. (In eng). DOI: 10.1038/s41375-021-01175-8.
160. Truong TT, Ryutov A, Pandey U, et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series. *EBioMedicine* 2021;67:103355. (In eng). DOI: 10.1016/j.ebiom.2021.103355.
161. Wang B, Van Oekelen O, Mouhieddine TH, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. *Journal of hematology & oncology* 2020;13(1):94. (In eng). DOI: 10.1186/s13045-020-00934-x.
162. Rahman F, Liu STH, Taimur S, et al. Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center in New York City. *Clinical transplantation* 2020:e14089. (In eng). DOI: 10.1111/ctr.14089.
163. Kutzler HL, Poulos CM, Cheema F, et al. COVID-19 in Solid Organ Transplant Recipients: Observations From Connecticut. *Transplantation* 2021;105(1):e6-e8. (In eng). DOI: 10.1097/tp.0000000000003495.
164. Malsy J, Veletzky L, Heide J, et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2020 (In eng). DOI: 10.1093/cid/ciaa1637.
165. Ho HE, Mathew S, Peluso MJ, Cunningham-Rundles C. Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. *The journal of allergy and clinical immunology In practice* 2021;9(1):490-493.e2. (In eng). DOI: 10.1016/j.jaip.2020.09.052.
166. Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). *Leukemia* 2022. DOI: 10.1038/s41375-022-01578-1.

167. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Accessed online at <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/> on February 9, 2022.
168. Clinical Practice Guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Accessed online at https://www.aabb.org/docs/default-source/default-document-library/regulatory/clinical-practice-guidelines-from-aabb-ccp.pdf?sfvrsn=e24ea825_0 on August 2, 2022.
169. Casadevall A, Pirofski LA, Joyner MJ. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. *mBio* 2021;12(2) (In eng). DOI: 10.1128/mBio.03372-20.
170. Mukhina OA, Fomina DS, Parshin VV, et al. SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case. *Human vaccines & immunotherapeutics* 2022:2101334. (In eng). DOI: 10.1080/21645515.2022.2101334.
171. Focosi D, Tuccori M, Antonelli G, Maggi F. What is the optimal usage of Covid-19 convalescent plasma donations? *Clin Microb Infect* 2020;S1198-743X(20):30589-9.
172. Sample, I. Doctors treat first UK patient in Covid 'super donor 'blood trial. *The Guardian*. Accessed online at <https://www.theguardian.com/world/2022/jun/30/doctors-treat-first-uk-patient-covid-super-donor-blood-trial-antibodies> on August 3, 2022.
173. Focosi D, Franchini M, Joyner MJ, Casadevall A, Sullivan DJ. Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources. 2021:2021.12.24.21268317v4. DOI: 10.1101/2021.12.24.21268317v4.